Ferrannini 2009

NCT00106340

1 Treatments

Studied treatment  vildagliptin 50 mg twice daily

Control treatment  glimepiride titrated up to 6 mg/day

Concomittant treatments  metformin (mean dose 1898 mg/day; mean duration of use 36 months)

2 Patients

Patients  Patients inadequately controlled on metformin monotherapy (HbA1c) 6.5-8.5%

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  double-blind

Design  Parallel groups

Centers  -

Geographical area  -

Sizes  1396/1393
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>/1396</td>
<td>/1393</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c goal &lt;7 all cause deaths</td>
<td>/1396</td>
<td>/1393</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>nephropathy</td>
<td>/1396</td>
<td>/1393</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>/1396</td>
<td>/1393</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>change in HbA1c</td>
<td>/1118</td>
<td>/1072</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>/1396</td>
<td>/1393</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>/1396</td>
<td>/1393</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>change in body weight</td>
<td>/-9</td>
<td>/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all hypoglycemia</td>
<td>23/1389</td>
<td>224/1382</td>
<td>0,10</td>
<td>[0,07; 0,16]</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td>/-9</td>
<td>/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References